Silk Road Medical, Inc

Equities

SILK

US82710M1009

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
17.8 USD +0.85% Intraday chart for Silk Road Medical, Inc +2.77% +45.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuro Protection System Plus CI
North American Morning Briefing : Stock Futures -2- DJ
Silk Road Medical Inc. and Genesis MedTech Group have signed an exclusive distribution agreement to introduce the TCAR® core products CI
Argus Upgrades Silk Road Medical to Buy From Hold, Price Target is $24 MT
Silk Road Medical Expands TCAR Portfolio with Launch of Tapered Enroute®? Transcarotid Stent System CI
Piper Sandler Raises Price Target on Silk Road Medical to $18 From $11, Maintains Neutral Rating MT
Transcript : Silk Road Medical, Inc, Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (SILK) SILK ROAD MEDICAL Reports Q4 Revenue $47.3M, vs. Street Est of $42M MT
Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2024 CI
Silk Road Medical, Inc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : S&P 500 Seen -2- DJ
Sector Update: Health Care Stocks Steady Late Afternoon MT
Silk Road Medical Shares Rise After Upgrade From Stifel MT
Stifel Upgrades Silk Road Medical to Buy From Hold, Raises Price Target to $20 From $9 MT
Transcript : Silk Road Medical, Inc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM
Lake Street Initiates Silk Road Medical at Buy Rating With $20 Price Target MT
Oppenheimer Adjusts Silk Road Medical Price Target to $25 From $30, Maintains Outperform Rating MT
Transcript : Silk Road Medical, Inc, Q3 2023 Earnings Call, Nov 08, 2023
Earnings Flash (SILK) SILK ROAD MEDICAL Reports Q3 Revenue $44.4M, vs. Street Est of $44.3M MT
Silk Road Medical, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2023 CI
Silk Road Medical Appoints Chas McKhann Chief Executive; Shares Rise MT
Silk Road Medical Announces Chief Executive Officer Changes CI
North American Morning Briefing : Google Parent's -2- DJ
Wolfe Research Upgrades Silk Road Medical to Peer Perform From Underperform MT
Chart Silk Road Medical, Inc
More charts
Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
17.8 USD
Average target price
18.43 USD
Spread / Average Target
+3.53%
Consensus